Estee Lauder subsidiary and OXIS resolve mitochondria patent dispute

OXIS INTERNATIONAL, INC. (OTC Bulletin Board: OXIS, Paris: OXI) and THE ESTEE LAUDER COMPANIES INC. (NYSE: EL) announce today that they have resolved a dispute between an Estee Lauder subsidiary, Applied Genetics Incorporated Dermatics ("AGI"), and Oxis over technology related to U.S. Patent No. 6,103,746 (the "746 Patent") and U.S. Patent No. 6,479,533 (the "533 Patent"), entitled "Methods and Compositions for the Protection of Mitochondria."  

An agreement between the parties provides Oxis with full title to the '746 and '533 Patents in exchange for Estee Lauder receiving a non-exclusive license under the '746 and '533 Patents within the cosmetic market.  The material terms and conditions are to remain confidential pursuant to the agreement.

SOURCE OXIS International, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Researchers show potential link between a genetic variation and atrial fibrillation